title: Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation.
authors.forename: J M
authors.initials: JM
authors.lastname: McDaniel
authors.forename: J X
authors.initials: JX
authors.lastname: Zou
authors.forename: W
authors.initials: W
authors.lastname: Fulp
authors.forename: D-T
authors.initials: DT
authors.lastname: Chen
authors.forename: A F
authors.initials: AF
authors.lastname: List
authors.forename: P K
authors.initials: PK
authors.lastname: Epling-Burnette
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology*; D000077269:Lenalidomide; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000276:immunology*; D011379:Prognosis; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide